Endometriosis - Pipeline Review, H1 2018 - Product Image

Endometriosis - Pipeline Review, H1 2018

  • ID: 4482754
  • Report
  • 133 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • Enteris BioPharma Inc
  • Immunitor Inc
  • Ogeda SA
  • SK Chemicals Co Ltd
  • MORE
Endometriosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H1 2018, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 11, 7, 1, 15, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • Enteris BioPharma Inc
  • Immunitor Inc
  • Ogeda SA
  • SK Chemicals Co Ltd
  • MORE
Introduction

Report Coverage

Endometriosis - Overview

Endometriosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Endometriosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Endometriosis - Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Astellas Pharma Inc

Bayer AG

ElexoPharm GmbH

EndoCeutics Inc

Enteris BioPharma Inc

Evotec AG

Forendo Pharma Ltd

Immunitor Inc

Kissei Pharmaceutical Co Ltd

Luye Pharma Group Ltd

Nippon Shinyaku Co Ltd

Ogeda SA

Philogen SpA

Repros Therapeutics Inc

SK Chemicals Co Ltd

Takeda Pharmaceutical Co Ltd

ValiRx Plc

Viramal Ltd

Endometriosis - Drug Profiles

acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile

BAY-1128688 - Drug Profile

BAY-1158061 - Drug Profile

BAY-1817080 - Drug Profile

BAY-1834845 - Drug Profile

danazol - Drug Profile

Drug 1 for Endometriosis - Drug Profile

Drug 2 for Endometriosis - Drug Profile

Drug 3 for Endometriosis - Drug Profile

Drug 4 for Endometriosis - Drug Profile

Drug for Endometriosis - Drug Profile

Drug to Antagonize P2X3 for Endometriosis - Drug Profile

Drug to Inhibit C-Jun for Endometriosis - Drug Profile

EC-304 - Drug Profile

EC-313 - Drug Profile

elagolix sodium - Drug Profile

fezolinetant - Drug Profile

FP-5677 - Drug Profile

goserelin ER - Drug Profile

KLH-2109 - Drug Profile

leuprolide - Drug Profile

MIA-602 - Drug Profile

NHP-07 - Drug Profile

NS-580 - Drug Profile

opigolix - Drug Profile

PGL-2001 - Drug Profile

progesterone - Drug Profile

Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile

relugolix - Drug Profile

SKI-2670 - Drug Profile

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Oncology and Uterine Fibroids - Drug Profile

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile

Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile

Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile

Small Molecules to Inhibit CD147 for Arthritis, Endometriosis, Immunology and Oncology - Drug Profile

Small Molecules to Inhibit HSD17B1 for Endometriosis - Drug Profile

SP-011 - Drug Profile

SP-012 - Drug Profile

SR-16234 - Drug Profile

Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy - Drug Profile

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile

telapristone acetate - Drug Profile

tetravil - Drug Profile

TOT-206 - Drug Profile

triptorelin acetate ER - Drug Profile

V-Endo - Drug Profile

VAL-301 - Drug Profile

vilaprisan - Drug Profile

VPE-001 - Drug Profile

Endometriosis - Dormant Projects

Endometriosis - Discontinued Products

Endometriosis - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Endometriosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Endometriosis - Pipeline by AbbVie Inc, H1 2018

Endometriosis - Pipeline by Addex Therapeutics Ltd, H1 2018

Endometriosis - Pipeline by Astellas Pharma Inc, H1 2018

Endometriosis - Pipeline by Bayer AG, H1 2018

Endometriosis - Pipeline by ElexoPharm GmbH, H1 2018

Endometriosis - Pipeline by EndoCeutics Inc, H1 2018

Endometriosis - Pipeline by Enteris BioPharma Inc, H1 2018

Endometriosis - Pipeline by Evotec AG, H1 2018

Endometriosis - Pipeline by Forendo Pharma Ltd, H1 2018

Endometriosis - Pipeline by Immunitor Inc, H1 2018

Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Endometriosis - Pipeline by Luye Pharma Group Ltd, H1 2018

Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, H1 2018

Endometriosis - Pipeline by Ogeda SA, H1 2018

Endometriosis - Pipeline by Philogen SpA, H1 2018

Endometriosis - Pipeline by Repros Therapeutics Inc, H1 2018

Endometriosis - Pipeline by SK Chemicals Co Ltd, H1 2018

Endometriosis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Endometriosis - Pipeline by ValiRx Plc, H1 2018

Endometriosis - Pipeline by Viramal Ltd, H1 2018

Endometriosis - Dormant Projects, H1 2018

Endometriosis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Endometriosis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Endometriosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Astellas Pharma Inc
  • Bayer AG
  • ElexoPharm GmbH
  • EndoCeutics Inc
  • Enteris BioPharma Inc
  • Evotec AG
  • Forendo Pharma Ltd
  • Immunitor Inc
  • Kissei Pharmaceutical Co Ltd
  • Luye Pharma Group Ltd
  • Nippon Shinyaku Co Ltd
  • Ogeda SA
  • Philogen SpA
  • Repros Therapeutics Inc
  • SK Chemicals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • ValiRx Plc
  • Viramal Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll